

Nyrada  
inc

# Investor Update Webinar

**5 February 2026 | Sydney, Australia**

**Improving Lives, Offering Hope**

**ASX:NYR**

Authorised by Mr. John Moore, Non-Executive Chair,  
on behalf of the Board.



# Important Notice and Disclaimer



This presentation has been prepared by Nyrada Inc ("**NYR**" or "**Company**"). It should not be considered as an offer or invitation to subscribe for, or purchase any securities in NYR, or as an inducement to purchase any securities in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. In particular, this presentation may not be released to US wire services or distributed in the United States.

This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or to, or for the account or benefit of, US persons. The Company's CDIs have not been, and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction of the United States. The CDIs may not be offered, sold or otherwise transferred in the United States except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act of 1933 and the applicable securities laws of any state or other jurisdiction in the United States. No person in the United States may, directly or indirectly, participate in the Company's Security Purchase Plan.

It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice, and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place.

Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

# Nyrada Overview

- › Clinical-stage biotech company developing TRPC ion channel inhibitors to treat a range of medical conditions
- › Lead drug candidate – Xolatryp® (formerly NYR-BI03)
  - › Potent 3<sup>rd</sup> generation TRPC 3, 6 and 7 channel inhibitor
  - › Novel and well-understood mechanism of action
  - › Solid scientific foundation
  - › Preclinical efficacy across multiple therapeutic areas
- › Progressing Clinical Development
  - › Phase I completed (safety, tolerability, PK)
  - › Phase IIa in acute myocardial infarction targeting ischemia reperfusion injury expected to commence in March 2026




# Ischemia Reperfusion – Last Cardiac Frontier



“Ischemia Reperfusion Injury is defined as the paradoxical exacerbation of cellular dysfunction and death following restoration of blood flow to previously ischemic tissues. Reestablishing blood flow is essential to salvage ischaemic tissue; however, reperfusion itself can paradoxically cause further damage, threatening tissue function and viability.” \*


## Coronary PCI (angioplasty)



Blood flow restoration

PCI (Balloon Angioplasty):

- First procedure in 1977, stents in 1994,
- Standard of care for STEMI by early 2000s



\* National Library of Medicine - <https://www.ncbi.nlm.nih.gov/books/NBK534267>



# Large Market Opportunity – Myocardial Ischemia Reperfusion Injury

## Globally:

**~15-20 million**  
people suffer heart  
attack annually

**~15%**  
mortality within 30  
days

No current FDA approved treatments

Effective treatment will improve patient outcomes and reduce high costs associated with long-term care of brain injury survivors.

## Large and growing treatment market\*:

Currently  
**~US\$1.7 billion**

Growing  
**~7.7% CAGR**

Forecast  
**~US\$2.3 billion by  
2029**

\* Research and Markets - [www.researchandmarkets.com/reports/6089883/ischemia-reperfusion-injury-market-report](http://www.researchandmarkets.com/reports/6089883/ischemia-reperfusion-injury-market-report)





# Phase I Clinical Trial

## Key Results:

**Xolatryp** met its Primary Endpoint with all doses safe and well tolerated, with no dose-limiting, or dose-related safety issues.

- **48 healthy participants** (36 received drug, 12 received placebo).
- **Nil SAEs**
- **10 AEs**
  - All mild or moderate
  - 5 *not related to Xolatryp*, 1 *unlikely related to Xolatryp*.
  - Most frequently reported AE was headache.
- **Pharmacokinetics** predictable with linear blood concentrations over time.
- **10 minutes** to reach therapeutic levels

**Xolatryp Levels in Cohort 6**



# Phase IIa Clinical Trial

## Key Features:

**Xolatrip** to be assessed for safety and preliminary efficacy in patients with ST-Elevation Myocardial Infarction (STEMI) who undergo primary Percutaneous Coronary Intervention (PCI)


### Scope (subject to change)

- 200 patients dosed (up to approximately; placebo and drug – 1:1)
- 9 to 18 months (indicative)
- 6 sites (initially)
- First patient screened: March 2026

Key operational risk – recruitment rate impacting duration and number of sites



# Stratification of Patients for Safety and Efficacy Endpoints





# Clinical Proposition\*

- › Strong relationship between infarct size and poor clinical outcomes, particularly 1-year mortality and heart failure
- › Reducing infarct size leads better heart muscle performance and clinically meaningful benefits
  - › 5% reduction in infarct size can reduce 12-month heart failure hospitalisation risk by 20%
  - › 10% reduction in infarct size can reduce 12-month heart failure hospitalisation risk by 44%
- › Patients with largest infarcts show dramatically worse prognosis
  - › Patients in the largest infarct quartile had a 1-year mortality approximately 10-fold higher than patients with patients in the smallest infarct quartile

\* Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials – [www.ncbi.nlm.nih.gov/27056772/](http://www.ncbi.nlm.nih.gov/27056772/)



# Origins of TRPC Channel Inhibition


**Lutz Birnbaumer**



**Birnbaumer's Mice**



# TRPC Channels - Cardioprotection



Cell Type	TRPC Activation Effect	Xolatryp Inhibition Effect
<b>Cardiomyocytes</b>	Calcium overload → cell death	Prevents damage, preserves function and contractility
<b>Endothelial</b>	Impaired repair → poor blood flow	Enhances vessel repair, reduces inflammation
<b>Fibroblasts</b>	Excessive scarring → stiff heart	Limits scarring, preserves flexibility



# R&D Activities

## Evolving Pipeline:

**Xolatryp** demonstrated preclinical efficacy:

- Myocardial ischemia reperfusion injury
- Ischemic stroke
- Moderate to severe TBI

Literature suggests **Xolatryp** may additionally have efficacy in:

- Oncology
- Ischemic reperfusion injury – other organs
- Cardiac hypertrophy and fibrosis
- Pain management
- Epilepsy

Pre-clinical animal studies have been initiated seeking to assess efficacy of **Xolatryp** in oncology indications

## **Xolatryp** formulation:

- Current delivery is via intravenous infusion
- Analysis commenced for development of oral dose form





# Financial Overview and Outlook



## Capital position

- › Cash balance of AU\$7.12 million at 31 December 2025
- › AU\$2.16 million R&D tax rebate expected in respect to FY2025 (subject to Government Agency Review)
- › AU\$0.46 million additional capital from option exercise in 3QFY2026 YTD

## Operating Results Summary

	FY2025 (AU\$)	FY2024 (AU\$)
R&D Costs	4,376,215	2,030,502
Corporate and admin expenses	1,061,480	577,842
Share-based payment expense	177,218	358,074
Professional services expense	381,618	477,948
Employment benefits expense	1,225,077	1,127,500

## › Programs

- › Xolatryp into Phase IIa clinical trial first dosing expected March 2026
- › Pre-clinical oncology efficacy studies pending



# Investment Proposition

- › Distinguished, high calibre, and globally experienced governing and scientific advisory boards
  - › Global biotech and pharma
  - › Extensive and pioneering TRPC knowledge
- › Demonstrated preclinical efficacy in multiple therapeutic areas
- › Significant target markets including for indications with unmet clinical need and serious and life-threatening conditions
- › Wholly owned intellectual property with a composition-of-matter patent pending, supported by an international search confirming both novelty and inventiveness
- › Well capitalised and lean operating model



# Preclinical Study 1

## Key Preclinical Results:



**Xolatryp** showed strong efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion (IR) injury

- **86%** Cardioprotection
- **43%** increase in left ventricular ejection fraction
- **50%** increase in fractional shortening

Key blood biomarker markers assessed

- **42%** decrease in AST levels
- **45%** decrease in LDH levels
- **32%** decrease in Troponin I

**Superior efficacy** compared to FDA-approved, Captopril



# Preclinical Study 2

## Key Preclinical Results:

**Xolatryp** showed strong efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion injury when administered as a short-duration intravenous infusion


- **42%** Cardioprotection
- **88%** decrease in arrhythmias at 1 hour
- **90%** decrease in arrhythmias at 3 hours

Key blood biomarker markers assessed

- **32%** decrease in Troponin I
- **21%** decrease in ALT levels

I/R + vehicle

I/R + NYR-BI03  
(9 mg/kg)





# Conclusion

## › **Nyrada – the company**

- › Pioneering TRPC channel inhibition therapies to treat a range of medical conditions
- › AU\$7.12 million cash position at end Dec 2025
- › AU\$2.16 million R&D rebated expected
- › AU\$0.46 million option exercise capital 3QFY2026 YTD

## › **Xolatryp – the lead drug asset**

- › Solid scientific foundations and well understood mechanism of action
- › Composition of matter patent pending
- › Preclinical efficacy demonstrated in AMI, ischemic stroke, and traumatic brain injury (TBI)
- › Phase I (safety, tolerability, PK) clinical trial completed
- › Phase IIa (safety and efficacy) clinical trial to commence



@nyrada\_inc



@nyrada\_inc

[info@nyrada.com](mailto:info@nyrada.com)

[www.nyrada.com](http://www.nyrada.com)